Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurth, M. C.
Right arrow Articles by Langston, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurth, M. C.
Right arrow Articles by Langston, J. W.
NEUROLOGY 1993;43:1698
© 1993 American Academy of Neurology

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations

M. C. Kurth, MD, PhD, J. W. Tetrud, MD, CM. Tanner, MD, I. Irwin, BA, G. T. Stebbins, PhD, C. G. Goetz, MD and J. W. Langston, MD

California Parkinson's Disease Foundation (Drs. Kurth, Tetrud, Tanner, and Langston, and I. Irwin), San Jose, CA; and the Section of Movement Disorders (Drs. Stebbins and Goetz), Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.

Ten patients with Parkinson's disease suffering severe motor fluctuations completed a double-blind, placebo-controlled, crossover trial of duodenal infusion of levodopa/carbidopa to determine if this technique improved the duration of functional time by reducing plasma levodopa level variability. With infusion, seven patients experienced increased functional "on" hours and decreased number of "off episodes; however, two patients were slightly worse and one patient experienced no benefit. All 10 patients had significantly decreased variability in levodopa levels permitting better titration of levodopa dosage to individual requirements. Five patients continued to use infusion 12 to 20 months after completion of this study. Selected patients with Parkinson's disease who experience severe motor fluctuations may benefit from duodenal infusion with an improved and prolonged response to medication.

Address correspondence and reprint requests to Dr. M.C. Kurth, Barrow Neurological Institute, Division of Neurology, Section of Movement Disorders, 222 West Thomas Road, Phoenix, AZ 85013-4496.

Supported in part by a patient donation to the California Parkinson's Foundation and a grant from the United Parkinson Foundation, Chicago, IL, to the Section of Movement Disorders, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center.

Received October 6, 1992. Accepted for publication in final form February 2, 1993.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
O.K. Sujith and C. Lane
Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease
Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 105 - 113.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
Parkinson Study Group
A Randomized Controlled Trial of Etilevodopa in Patients With Parkinson Disease Who Have Motor Fluctuations
Arch Neurol, February 1, 2006; 63(2): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
F. Stocchi, L. Vacca, S. Ruggieri, and C. W. Olanow
Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease: A Clinical and Pharmacokinetic Study
Arch Neurol, June 1, 2005; 62(6): 905 - 910.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. M. Mouradian
Should levodopa be infused into the duodenum?
Neurology, January 25, 2005; 64(2): 182 - 183.
[Full Text] [PDF]

Home page
 NeurologyHome page
D. Nyholm, A. I.M. Nilsson Remahl, N. Dizdar, R. Constantinescu, B. Holmberg, R. Jansson, S. -M. Aquilonius, and H. Askmark
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Neurology, January 25, 2005; 64(2): 216 - 223.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P Chana, C Kuntsmann, M Reyes-Parada, and P Saez-Briones
Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered
J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(12): 1782 - 1783.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. T. Bartus, D. Emerich, P. Snodgrass-Belt, K. Fu, H. Salzberg-Brenhouse, D. Lafreniere, L. Novak, E.-S. Lo, T. Cooper, and A. S. Basile
A Pulmonary Formulation of L-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson's Disease
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 828 - 835.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Stocchi and C. W. Olanow
Continuous dopaminergic stimulation in early and advanced Parkinson's disease
Neurology, January 13, 2004; 62(90011): S56 - 63.
[Abstract] [Full Text]

Home page
 NeurologyHome page
C. W. Olanow and F. Stocchi
COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?
Neurology, January 13, 2004; 62(90011): S72 - 81.
[Abstract] [Full Text]

Home page
 NeurologyHome page
P. Barone
Clinical strategies to prevent and delay motor complications
Neurology, September 23, 2003; 61(90063): S12 - 16.
[Abstract] [Full Text]

Home page
 BrainHome page
F. Stocchi, S. Ruggieri, L. Vacca, and C. W. Olanow
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
Brain, September 1, 2002; 125(9): 2058 - 2066.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.